diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM11493diaendo-11493Research ArticleОбзорыReviewРоль терапии на основе инкретинов в лечении сахарного диабета 2 типа: прошлое, настоящее и будущееThe role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and futurehttps://orcid.org/0000-0002-5835-8019MeierJuris J.juris.meier@rub.deДиабетический центр Бохум-Хаттинген, больница Святого Иосифа, Рурский университетГерманияDiabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University BochumGermany201917012020225461466Copyright © Meier J., 20192019Meier J.Meier J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/11493

Постоянно увеличивающаяся распространенность сахарного диабета 2 типа (СД2) во всем мире привела к появлению нескольких противодиабетических лекарственных препаратов с различными механизмами действия. Инкретиновые гормоны и их влияние на метаболизм глюкозы и патогенез СД2 стали знаковым открытием в лечении этого все более распространенного нарушения обмена веществ. Агонисты рецептора глюкагоноподобного пептида-1 (ГПП-1) и ингибиторы дипептидилпептидазы-4 (ДПП-4) представляют собой два основных класса препаратов для лечения на основе инкретинов, которые различными способами регулируют механизм усвоения глюкозы, при этом снижают массу тела (агонисты рецептора ГПП-1) или не влияют на массу тела (ингибиторы ДПП-4) и связаны с низким риском гипогликемии и других нежелательных явлений. Кроме того, данные указывают на их возможный терапевтический потенциал при лечении других клинических состояний, таких как ожирение, сердечно-сосудистые заболевания и заболевания печени. В этом обзоре рассматриваются имеющиеся на сегодняшний день агонисты рецептора ГПП-1 и ингибиторы ДПП-4 и их использование в возможных стратегиях лечения СД2, а также их будущее в контексте лечения диабета и других заболеваний.

The ever-increasing burden of type 2 diabetes mellitus (T2DM) worldwide, has led to the emergence of several antidiabetes drugs with different modes of action. Incretin hormones and their effect on glucose metabolism and pathogenesis of T2DM has been a landmark discovery in the management of this increasingly prevalent metabolic disorder. Glucagon like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are the two major classes of incretin-based therapies that regulate glucose mechanism through multiple pathways, demonstrate weight loss (GLP-1 receptor agonists) or a weight-neutral effect (DPP-4 inhibitors), and are associated with a low risk of hypoglycaemia and other adverse events. In addition, evidence reflects their possible therapeutic potential in the treatment of other clinical conditions such as obesity, cardiovascular disease and liver disorders. This review explores the availability and the impact of GLP-1 receptor agonists and DPP-4 inhibitors as potential therapeutic strategies for T2DM along with their future in the landscape of diabetes management and other clinical conditions.

сердечно-сосудистая системаингибиторы дипептидилпептидазы-4глюкозозависимый инсулинотропный полипептидглюкагоноподобный пептид-1агонисты рецептора ГПП-1терапия на основе инкретиновсахарный диабет 2 типаcardiovasculardipeptidyl peptidase-4 inhibitorsglucose-dependent insulinotropic polypeptideglucagon like peptide -1GLP-1 receptor agonistsincretin-based therapiestype 2 diabetes mellitusReferencesInternational Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation; 2017 [cited 22 August 2019]. Available from: http://www.diabetesatlas.orgInternational Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation; 2017 [cited 22 August 2019]. Available from: http://www.diabetesatlas.orgMuller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109−115. doi: https://doi.org/10.1056/NEJM197007162830301Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109−115. doi: https://doi.org/10.1056/NEJM197007162830301Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007;107(Suppl 3):S6–S9.Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007;107(Suppl 3):S6–S9.Deacon CF, Ahrén B. Physiology of incretins in health and disease. Rev Diabet Stud. 2011;8(3):293−306. doi: https://doi.org/10.1900/RDS.2011.8.293Deacon CF, Ahrén B. Physiology of incretins in health and disease. Rev Diabet Stud. 2011;8(3):293−306. doi: https://doi.org/10.1900/RDS.2011.8.293Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696−1705. doi: https://doi.org/10.1016/S0140-6736(06)69705-5Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696−1705. doi: https://doi.org/10.1016/S0140-6736(06)69705-5Takeda J, Seino Y, Tanaka K, et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A. 1987;84(20):7005−7008. doi: https://doi.org/10.1073/pnas.84.20.7005Takeda J, Seino Y, Tanaka K, et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A. 1987;84(20):7005−7008. doi: https://doi.org/10.1073/pnas.84.20.7005Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300−1304. doi: https://doi.org/10.1016/s0140-6736(87)91194-9Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300−1304. doi: https://doi.org/10.1016/s0140-6736(87)91194-9Nauck, MA, Heimesaat MA, Ørskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307. doi: https://doi.org/10.1172/jci116186Nauck, MA, Heimesaat MA, Ørskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307. doi: https://doi.org/10.1172/jci116186Nauck MA, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–744. doi: https://doi.org/10.1007/bf00401145Nauck MA, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–744. doi: https://doi.org/10.1007/bf00401145Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728−742. doi: https://doi.org/10.1038/nrendo.2012.140Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728−742. doi: https://doi.org/10.1038/nrendo.2012.140Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929−2940. doi: https://doi.org/10.2337/diacare.26.10.2929Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929−2940. doi: https://doi.org/10.2337/diacare.26.10.2929Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492−498. doi: https://doi.org/10.1210/jcem-63-2-492Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492−498. doi: https://doi.org/10.1210/jcem-63-2-492Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56(8):1951–1959. doi: https://doi.org/10.2337/db07-0100Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56(8):1951–1959. doi: https://doi.org/10.2337/db07-0100Vardarli I, Nauck MA, Köthe LD, et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as “isoglycemic” intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(4):945−954. doi: https://doi.org/10.1210/jc.2010-2178Vardarli I, Nauck MA, Köthe LD, et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as “isoglycemic” intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(4):945−954. doi: https://doi.org/10.1210/jc.2010-2178Ahrén B. The future of incretin-based therapy: novel avenues — novel targets. Diabetes Obes Metab. 2011;13(Suppl 1):158–166. doi: https://doi.org/10.1111/j.1463-1326.2011.01457.xAhrén B. The future of incretin-based therapy: novel avenues — novel targets. Diabetes Obes Metab. 2011;13(Suppl 1):158–166. doi: https://doi.org/10.1111/j.1463-1326.2011.01457.xAndersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390−403. doi: https://doi.org/10.1038/s41574-018-0016-2Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390−403. doi: https://doi.org/10.1038/s41574-018-0016-2Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin — diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009;23(4):487−498. doi: https://doi.org/10.1016/j.beem.2009.03.003Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin — diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009;23(4):487−498. doi: https://doi.org/10.1016/j.beem.2009.03.003Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76 Suppl 5:S12−19. doi: https://doi.org/10.3949/ccjm.76.s5.03Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76 Suppl 5:S12−19. doi: https://doi.org/10.3949/ccjm.76.s5.03Davies M, Pieber TR, Hartoft-Nielsen M-L, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470. doi: https://doi.org/10.1001/jama.2017.14752Davies M, Pieber TR, Hartoft-Nielsen M-L, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470. doi: https://doi.org/10.1001/jama.2017.14752Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? Diabetologia. 2015;58(8):1745−1750. doi: https://doi.org/10.1007/s00125-015-3608-6Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? Diabetologia. 2015;58(8):1745−1750. doi: https://doi.org/10.1007/s00125-015-3608-6Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–2193. doi: https://doi.org/10.1016/S0140-6736(18)32260-8Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–2193. doi: https://doi.org/10.1016/S0140-6736(18)32260-8Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140):2607–2618. doi: https://doi.org/10.1016/S0140-6736(18)30726-8Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140):2607–2618. doi: https://doi.org/10.1016/S0140-6736(18)30726-8Guidance document: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD, U.S. Food and Drug Administration; 2008 [content current as of 2018 September 19]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetesGuidance document: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD, U.S. Food and Drug Administration; 2008 [content current as of 2018 September 19]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetesMarso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311−322. doi: https://doi.org/10.1056/NEJMoa1603827Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311−322. doi: https://doi.org/10.1056/NEJMoa1603827Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834−1844. doi: https://doi.org/10.1056/NEJMoa1607141Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834−1844. doi: https://doi.org/10.1056/NEJMoa1607141Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519−1529. doi: https://doi.org/10.1016/S0140-6736(18)32261-XHernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519−1529. doi: https://doi.org/10.1016/S0140-6736(18)32261-XPfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247−2257. doi: https://doi.org/10.1056/NEJMoa1509225Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247−2257. doi: https://doi.org/10.1056/NEJMoa1509225Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228−1239. doi: https://doi.org/10.1056/NEJMoa1612917Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228−1239. doi: https://doi.org/10.1056/NEJMoa1612917Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2018;61(12):2461−2498. doi: https://doi.org/10.1007/s00125-018-4729-5Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2018;61(12):2461−2498. doi: https://doi.org/10.1007/s00125-018-4729-5Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232−242. doi: https://doi.org/10.1056/NEJMoa1501352Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232−242. doi: https://doi.org/10.1056/NEJMoa1501352Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317−1326. doi: https://doi.org/10.1056/NEJMoa1307684Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317−1326. doi: https://doi.org/10.1056/NEJMoa1307684White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327−1335. doi: https://doi.org/10.1056/NEJMoa1305889White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327−1335. doi: https://doi.org/10.1056/NEJMoa1305889Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69−79. doi: https://doi.org/10.1001/jama.2018.18269Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69−79. doi: https://doi.org/10.1001/jama.2018.18269McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085−1092. doi: https://doi.org/10.1111/dom.12548McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085−1092. doi: https://doi.org/10.1111/dom.12548Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788−1803. doi: https://doi.org/10.1161/CIRCRESAHA.114.301958Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788−1803. doi: https://doi.org/10.1161/CIRCRESAHA.114.301958Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(1):23−31. doi: https://doi.org/10.1111/jgh.13026Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(1):23−31. doi: https://doi.org/10.1111/jgh.13026Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679−690. doi: https://doi.org/10.1016/S0140-6736(15)00803-XArmstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679−690. doi: https://doi.org/10.1016/S0140-6736(15)00803-XAthauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664−1675. doi: https://doi.org/10.1016/S0140-6736(17)31585-4Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664−1675. doi: https://doi.org/10.1016/S0140-6736(17)31585-4

The authors declare that there are no conflicts of interest present.